简介：　　摘要：目的 观察心脉隆联合比索洛尔对冠心病合并心衰患者血清炎症因子及心功能的影响。方法 选择 2018年 11月至 2020年 2月我院收治的冠心病合并心衰患者 88例，根据就诊顺序分为对照组 44例和试验组 44例。对照组应用比索洛尔口服进行治疗，试验组应用心脉隆 +比索洛尔进行联合治疗。观察两组治疗效果。结果 治疗后，对照组超敏 C反应蛋白（ hypersensitive C-reactive protein， hs-CRP）、 B型利钠肽（ Brain natriuretic peptide， BNP）、左室射血分数（ Left Ventricular Ejection Fractions， LVEF）水平均低于试验组，左心室收缩末期容积（ left ventricular end-systolic volume， LVESV）及左心室舒张末期容积（ left ventricular end-diastolic volume， LVEDV）水平高于试验组，差异有统计学意义（ P<0.05）。结论 在冠心病合并心衰患者中应用心脉隆与比索洛尔联合治疗可有效改善炎症因子水平，增强心功能。  　　关键词：冠心病合并心衰 ;心脉隆 ;比索洛尔 ;血清炎症因子 ;心功能  　 Abstract: Objective To observe the effect of Xinmailong combined with bisoprolol on serum inflammatory factors and cardiac function in patients with coronary heart disease and heart failure. Methods 88 patients with coronary heart disease complicated with heart failure admitted to our hospital from November 2018 to February 2020 were selected and divided into control group (44 cases) and experimental group (44 cases) according to the order of treatment. The control group was treated with bisoprolol orally, and the experimental group was treated with Xinmailong and bisoprolol. The therapeutic effects of the two groups were observed. Results after treatment, the levels of hypersensitive C-reactive protein (hs CRP), brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF) in the control group were lower than those in the experimental group, and the left ventricular end systolic volume (LVEF) in the control group was lower than that in the experimental group The levels of LVESV and LVEDV in the experimental group were significantly higher than those in the experimental group (P < 0.05). Conclusion in patients with coronary heart disease complicated with heart failure, the combined treatment of Xinmailong and bisoprolol can effectively improve the level of inflammatory factors and enhance cardiac function.

简介：　　 [摘要 ] 目的 分析血清肿瘤标志物与恶性肿瘤相关因子联合检测在胃肠道肿瘤诊断中的应用价值。方法 选取 2017年 1月— 2018年 3月在该院进行治疗的胃肠道良性病以及胃肠道恶性肿瘤的患者 134例，其中恶性肿瘤组（ 78例）和良性病组（ 56例），对恶性肿瘤组和良性病组的 CEA、 CA153、 CA125、 TSGF进行检测以及观察联合检测和单项检测的敏感性、特异性和准确性。结果 恶性肿瘤中的胃癌、结直肠癌、十二指肠癌的患者肿瘤标志物 CEA、 CA153、 CA125均显著高于良性病组；恶性肿瘤中的胃癌、结直肠癌、十二指肠癌的患者恶性肿瘤因子 TSGF均显著高于良性病组（ P<0.05）；联合检测中的敏感性和准确性均显著高于肿瘤标志物或恶性肿瘤因子的单项检测中，但特异性略低（ P<0.05）， CEA、 CA125、 CA153以及 TSGF的单项检测的敏感性和准确性均显著低于联合检测（ P<0.05）。结论 血清肿瘤标志物以及恶性肿瘤相关因子联合检测可以提高胃肠道恶性肿瘤的诊断率以及敏感性。 　　 [关键词 ] 胃肠道恶性肿瘤；肿瘤标志物；恶性肿瘤因子；临床检验 　 [abstract] Objective To analyze the value of combined detection of serum tumor markers and malignant tumor-related factors in the diagnosis of gastrointestinal tumors. Methods 134 patients with benign gastrointestinal diseases and malignant gastrointestinal tumors treated in our hospital from January 2017 to March 2018 were selected, including 78 patients with malignant tumors and 56 patients with benign tumors. CEA, CA153, CA125 and TSGF of malignant tumors and benign tumors were detected, and the sensitivity, specificity and accuracy of combined detection and single detection were observed. Results The cancer markers CEA, CA153 and CA125 in patients with malignant tumors were significantly higher than those in patients with benign tumors; the malignant factors TSGF in patients with malignant tumors were significantly higher than those in patients with benign tumors (P < 0.05); the sensitivity and accuracy of combined detection were significantly higher than those of tumor markers or malignant tumors. The sensitivity and accuracy of CEA, CA125, CA153 and TSGF were significantly lower than those of combined detection (P < 0.05). Conclusion The combined detection of serum tumor markers and cancer-related factors can improve the diagnostic rate and sensitivity of gastrointestinal malignant tumors.